Evidence map›Paper›PMID 30987206›Full record

ReviewPharmaceutics2019

Relating Advanced Electrospun Fiber Architectures to the Temporal Release of Active Agents to Meet the Needs of Next-Generation Intravaginal Delivery Applications.

Kevin M Tyo, Farnaz Minooei, Keegan C Curry, Sarah M NeCamp, Danielle L Graves, Joel R Fried, Jill M Steinbach-Rankins

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Rapid-dissolving electrospun nanofibers for intra-vaginal antibiotic or probiotic delivery.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2023
    Article
  3. Article
  4. Review
  5. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kevin M TyoDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA. kevin.tyo@louisville.edu.
Farnaz MinooeiDepartment of Chemical Engineering, University of Louisville, Louisville, KY 40292, USA. farnaz.minooei@louisville.edu.
Keegan C CurryDepartment of Biology, University of Louisville, Louisville, KY 40292, USA. keegan.curry@louisville.edu.
Sarah M NeCampDepartment of Bioengineering, Speed School of Engineering, University of Louisville, Louisville, KY 40292, USA. sarah.necamp@louisville.edu.
Danielle L GravesDepartment of Bioengineering, Speed School of Engineering, University of Louisville, Louisville, KY 40292, USA. danielle.graves@louisville.edu.
Joel R FriedDepartment of Chemical Engineering, University of Louisville, Louisville, KY 40292, USA. joel.fried@louisville.edu.
Jill M Steinbach-RankinsDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA. jmstei01@louisville.edu.

Funding

Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative IntravaginalP20GM125504 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Shirin Ghods · 2018 to 2026
$24.4M
NIGMS NIH HHS P20 GM125504NIH HHS GM125504
6 · The paper itself

Abstract

Electrospun fibers have emerged as a relatively new delivery platform to improve active agent retention and delivery for intravaginal applications. While uniaxial fibers have been explored in a variety of applications including intravaginal delivery, the consideration of more advanced fiber architectures may offer new options to improve delivery to the female reproductive tract. In this review, we summarize the advancements of electrospun coaxial, multilayered, and nanoparticle-fiber architectures utilized in other applications and discuss how different material combinations within these architectures provide varied durations of release, here categorized as either transient (within 24 h), short-term (24 h to one week), or sustained (beyond one week). We seek to systematically relate material type and fiber architecture to active agent release kinetics. Last, we explore how lessons derived from these architectures may be applied to address the needs of future intravaginal delivery platforms for a given prophylactic or therapeutic application. The overall goal of this review is to provide a summary of different fiber architectures that have been useful for active agent delivery and to provide guidelines for the development of new formulations that exhibit release kinetics relevant to the time frames and the diversity of active agents needed in next-generation multipurpose applications.

Indexed as

delivery vehicledrug deliveryelectrospun fibersfiber architectureintravaginal delivery

Identifiers

PMID30987206
PMCPMC6523330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.